Teladoc Health's second quarter of 2025 saw a 2% decrease in consolidated revenue to $631.9 million, with adjusted EBITDA also declining by 23% to $69.3 million. Despite these decreases, the company significantly reduced its net loss to $32.7 million from $837.7 million in the prior year, primarily due to the absence of a large goodwill impairment charge. Integrated Care segment revenue grew, while BetterHelp revenue declined.
Consolidated revenue for Q2 2025 decreased by 2% to $631.9 million compared to Q2 2024.
Net loss significantly improved to $32.7 million ($0.19 per share) in Q2 2025, down from $837.7 million ($4.92 per share) in Q2 2024, largely due to the absence of a major goodwill impairment.
Adjusted EBITDA decreased by 23% to $69.3 million in Q2 2025.
Integrated Care segment revenue increased by 4% to $391.5 million, while BetterHelp segment revenue decreased by 9% to $240.4 million.
The company provided a financial outlook based on current market conditions and expectations, but specific numerical guidance for the next quarter or full year was not detailed in the provided text.
Analyze how earnings announcements historically affect stock price performance